| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis C Harrison, JJ Kiladjian, HK Al-Ali, H Gisslinger, R Waltzman, ... New England Journal of Medicine 366 (9), 787-798, 2012 | 2102 | 2012 |
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor M Galli, T Barbui, P Comfurius, C Maassen, HC Hemker, RFA Zwaal, ... The Lancet 335 (8705), 1544-1547, 1990 | 1766 | 1990 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1613 | 2022 |
| Efficacy and safety of low-dose aspirin in polycythemia vera R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ... New England Journal of Medicine 350 (2), 114-124, 2004 | 1330 | 2004 |
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature M Galli, D Luciani, G Bertolini, T Barbui Blood, The Journal of the American Society of Hematology 101 (5), 1827-1832, 2003 | 1257 | 2003 |
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis … A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007 | 1208 | 2007 |
| Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis S Cortelazzo, G Finazzi, M Ruggeri, O Vestri, M Galli, F Rodeghiero, ... New England Journal of Medicine 332 (17), 1132-1137, 1995 | 1124 | 1995 |
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ... Journal of clinical oncology 29 (6), 761-770, 2011 | 1077 | 2011 |
| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... New England Journal of Medicine 368 (1), 22-33, 2013 | 1002 | 2013 |
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera R Marchioli, G Finazzi, R Landolfi, J Kutti, H Gisslinger, C Patrono, ... Journal of Clinical Oncology 23 (10), 2224-2232, 2005 | 913 | 2005 |
| Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ... Blood, The Journal of the American Society of Hematology 124 (16), 2507-2513, 2014 | 870 | 2014 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 850 | 2013 |
| Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA … MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ... Blood, The Journal of the American Society of Hematology 96 (4), 1247-1253, 2000 | 837 | 2000 |
| Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin EM Bevers, M Galli, T Barbui, P Comfurius, RFA Zwaal Thrombosis and haemostasis 66 (12), 629-632, 1991 | 804 | 1991 |
| A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid … G Finazzi, R Marchioli, V Brancaccio, P Schinco, F Wisloff, J Musial, ... Journal of Thrombosis and Haemostasis 3 (5), 848-853, 2005 | 720 | 2005 |
| Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ... Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012 | 711 | 2012 |
| The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion T Barbui, J Thiele, H Gisslinger, HM Kvasnicka, AM Vannucchi, ... Blood cancer journal 8 (2), 15, 2018 | 695 | 2018 |
| Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome JA Coppell, PG Richardson, R Soiffer, PL Martin, NA Kernan, A Chen, ... Biology of blood and marrow transplantation 16 (2), 157-168, 2010 | 695 | 2010 |
| The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia P Rebulla, G Finazzi, F Marangoni, G Avvisati, L Gugliotta, G Tognoni, ... New England Journal of Medicine 337 (26), 1870-1875, 1997 | 689 | 1997 |
| Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy F Mandelli, D Diverio, G Avvisati, A Luciano, T Barbui, C Bernasconi, ... Blood, The Journal of the American Society of Hematology 90 (3), 1014-1021, 1997 | 653 | 1997 |
